Evidence map›Paper›PMID 32775617›Full record

ArticleMolecular therapy oncolytics2020

Neural Stem Cells Improve the Delivery of Oncolytic Chimeric Orthopoxvirus in a Metastatic Ovarian Cancer Model.

Mohamed Hammad, Yvonne R Cornejo, Jennifer Batalla-Covello, Asma Abdul Majid, Connor Burke, Zheng Liu, Yate-Ching Yuan, Min Li, Thanh H Dellinger, Jianming Lu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  5. Article
  6. Review
  7. Virus nanotechnology for intratumoural immunotherapy.Nature reviews bioengineering · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. The Potentials and Pitfalls of Using Adult Stem Cells in Cancer Treatment.Advances in experimental medicine and biology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mohamed HammadDepartment of Developmental and Stem Cell Biology, City of Hope, Duarte, CA 91010, USA.
Yvonne R CornejoDepartment of Developmental and Stem Cell Biology, City of Hope, Duarte, CA 91010, USA.
Jennifer Batalla-CovelloDepartment of Developmental and Stem Cell Biology, City of Hope, Duarte, CA 91010, USA.
Asma Abdul MajidDepartment of Developmental and Stem Cell Biology, City of Hope, Duarte, CA 91010, USA.
Connor BurkeDepartment of Developmental and Stem Cell Biology, City of Hope, Duarte, CA 91010, USA.
Zheng LiuTranslational Bioinformatics Division, Center for Informatics, City of Hope, Duarte, CA 91010, USA.
Yate-Ching YuanTranslational Bioinformatics Division, Center for Informatics, City of Hope, Duarte, CA 91010, USA.
Min LiDepartment of Information Sciences, Division of Biostatistics at the Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Thanh H DellingerDivision of Gynecologic Surgery, Department of Surgery, City of Hope, Duarte, CA 91010, USA.
Jianming LuDepartment of Surgery, City of Hope, Duarte, CA 91010, USA.
Nanhai G ChenDepartment of Surgery, City of Hope, Duarte, CA 91010, USA.
Yuman FongDepartment of Surgery, City of Hope, Duarte, CA 91010, USA.
Karen S AboodyDepartment of Developmental and Stem Cell Biology, City of Hope, Duarte, CA 91010, USA.
Rachael MooneyDepartment of Developmental and Stem Cell Biology, City of Hope, Duarte, CA 91010, USA.
City of Hope · USBeckman Research Institute

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer TherapyR01CA197359 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ABOODY, KAREN S · 2015 to 2019
$2.1M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA197359
6 · The paper itself

Abstract

Oncolytic virotherapy represents a promising approach for treating recurrent and/or drug-resistant ovarian cancer. However, its successful application in the clinic has been hampered by rapid immune-mediated clearance, which reduces viral delivery to the tumor. Patient-derived mesenchymal stem cells that home to tumors have been used as viral delivery tools, but variability associated with autologous cell isolations limits the clinical applicability of this approach. We previously developed an allogeneic, clonal neural stem cell (NSC) line (HB1.F3.CD21) that can be used to deliver viral cargo. Here, we demonstrate that this NSC line can improve the delivery of a thymidine kinase gene-deficient conditionally replication-competent orthopoxvirus, CF33, in a preclinical cisplatin-resistant peritoneal ovarian metastases model. Overall, our findings provide the basis for using off-the-shelf allogeneic cell-based delivery platforms for oncolytic viruses, thus providing a more efficient delivery alternative compared with the free virus administration approach.

Indexed as

Cancercellular therapyCF33ImmunityImmunotherapyneural stem cellsOncolysisoncolytic virotherapyOncolytic virusovarian cancer

Identifiers

PMID32775617
PMCPMC7394740
OpenAlexW3038899296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.